Does cholesterol act as a protector of cholinergic projections in Alzheimer's disease?

Lipids in Health and Disease

Volumn 4, Issue , 2005, Pages

  Bohr, Iwo J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL; LIPOPROTEIN; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR;

ALZHEIMER DISEASE; ARTICLE; CHOLESTEROL TRANSPORT; CHOLINERGIC NERVE; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; CORRELATION ANALYSIS; DETERIORATION; EPIGENETICS; GENETIC RISK; HUMAN; HYPERMETABOLISM; LIPID RAFT; NERVE CELL MEMBRANE; NERVE PROJECTION; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PRESYNAPTIC NERVE; PROTEIN FUNCTION; PROTEIN METABOLISM; RISK FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; APOLIPOPROTEINS E; CHOLESTEROL; CHOLINERGIC FIBERS; HUMANS; NEURONS;

EID: 23944495409     PISSN: 1476511X     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-4-13     Document Type: Article

References (29)

1. Hartman T: Cholesterol and Alzheimer's disease: statins, cholesterol depletion in APP processing and Abeta generation. Subcell Biochem 2005, 38:365-380.
2. Vauthey C, de Freitas GR, van Melle G, Devuyst G, Bogousslavsky J: Better outcome after stroke with higher serum cholesterol levels. Neurology 2000, 54:1944-1948.
3. Bohr I: Hypercholesterolemic diet applied to rat dams protects their offspring against cognitive deficits. Simulated neonatal anoxia model. Physiol Behav 2004, 82:703-711.
4. Heverin M, Meaney S, Lutjohann D, Diczfalusy U, Wahren J, Bjorkhem I: Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J Lipid Res 2005, 46:1047-1052.
5. Demeester N, Castrol G, Desrumaux C, De Geitere C, Fruchart JC, Santens P, Mulleners E, Engelborghs S, De Deyn PP, Vandekerckhove J, Rosseneu M, Labeur C: Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin : cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. J Lipid Res 2000, 41:963-974.
6. Mason RP, Shoemaker WJ, Shajenko L, Chambers TE, Herbette LG: Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol Aging 1992, 13:413-420.
7. Ledesma MD, Dotti CG: The conflicting role of brain cholesterol in Alzheimer's disease: lessons from the brain plasminogen system. Biochem Soc Symp 2005, 72:129-138.
8. Collerton D: Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience 1986, 19:1-28.
9. Verdile G, Fuller S, Atwood CS, Laws SM, Gandy SE, Martins RN: The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught? Pharmacol Res 2004, 50:397-340.
10. Kalaria RN, Bhatti SU, Lust WD, Perry G: The amyloid precursor protein in ischemic brain injury and chronic hypoperfusion. Ann NY Acad Sci 1993, 695:190-193.
11. Smith-Swintosky VL, Pettigrew LC, Craddock SD, Culwell AR, Rydel RE, Mattson MP: Secreted forms of -amyloid precursor protein protect against ischemic brain injury. J Neurochem 1994, 63:781-784.
12. Meziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, Ungerer A: Memory-enhancing effects of secreted forms of the -amyloid precursor protein in normal and amnesic mice. Proc Natl Acad Sci USA 1998, 95:12683-12688.
13. Koudinov AR, Berezov TT: Alzheimer's amyloid-beta (A beta) is an essential synaptic protein, not neurotoxic junk. Acta Neurobiol Exp (Wars) 2004, 64:71-97.
14. Nyakas CB, Buwalda B, Luiten PG: Hypoxia and brain development. Prog Neurobiol 1996, 49:1-51.
15. Slotkin TA: Cholinergic systems in brain development and disruption by neurotoxicants: nicotine, environmental tobacco smoke, organophosphates. Toxicol Appl Pharmacol 2004, 198:132-151.
16. Shohami E, Kaufer D, Chen Y, Seidman S, Cohen O, Ginzberg D, Melamed-Book N, Yirmiya R, Soreq H: Antisense prevention of neuronal damages following head injury in mice. J Mol Med 2000, 78:228-236.
17. Dietschy JM, Turley SD: Cholesterol metabolism in the brain. Curr Opin Lipidol 2001, 12:105-112.
18. Tsui-Pierchala BA, Encinas M, Milbrandt J, Johnson EM Jr: Lipid rafts in neuronal signaling and function. Trends Neurosci 2002, 25:412-417.
19. Hooper NM: Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein. Biochem Soc Trans 2005, 33:335-338.
20. Lane RM, Farlow MR: Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. J Lipid Res 2005, 46:949-968.
21. Bastiaanse EM, Hold KM, Van der Laarse A: The effect of membrane cholesterol content on ion transport processes in plasma membranes. Cardiovasc Res 1997, 33:272-283.
22. Barrantes FJ: Structural basis for lipid modulation of nicotinic acetylcholine receptor function. Brain Res Brain Res Rev 2004, 47:71-95.
23. Maguire PA, Druse MJ: The influence of cholesterol on synaptic fluidity, dopamine D1 binding and dopamine-stimulated adenylate cyclase. Brain Res Bull 1989, 23:69-74.
24. Poirier J: Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann N Y Acad Sci 2000, 924:81-90.
25. Howland DS, Trusko SP, Savage MJ, Reaume AG, Lang DM, Hirsch JD, Maeda N, Siman R, Greenberg BD, Scott RW: Modulation of secreted -amyloid precursor protein and amyloid -peptide in brain by cholesterol. J Biol Chem 1998, 273:16576-16582.
26. Bodovitz S, Klein WL: Cholesterol modulates -secretase cleavage of amyloid precursor protein. J Biol Chem 1996, 271:4436-4440.
27. Eckert GP, Wood WG, Muller WE: Statins: drugs for Alzheimer's disease? J Neural Transm 2005, in press:.
28. McCully KS: Homocysteine, vitamins, and prevention of vascular disease. Mil Med 2004, 169:325-329.
29. Ravnskov U: A hypothesis out-of-date. the diet-heart idea. J Clin Epidemiol 2002, 55:1057-1063.